Pay in 4 interest-free payments of $5.63 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
On December 22nd, the Food and Drug Administration (FDA) approved Novo Nordisks oral semaglutide tablet, a 25 mg dose of the same active ingredient found in injectable Wegovy and Ozempic
Potential Benefits: STEP trials (n=1961) demonstrated approximately 15% body weight reduction over 68 weeks Reduces HbA1c 1.52% in diabetic patients Well-established safety profile Suggested Clinical Dosing Range: Titrated from 0.25 mg to 2.4 mg weekly subcutaneous Dosing is individualized and determined by a qualified medical provider
(July 2017)
Eligibility for a GLP-1 medication depends on a Service Members diagnosis, prior authorization, and/or medical necessity
US$ 26.03
US$ 21.14
US$ 20.39
US$ 28.57
US$ 24.89
US$ 21.86
